高级搜索
结外鼻型NK/T细胞淋巴瘤组织中MMP-26、MMP-9、TIMP-4 的表达及意义[J]. 肿瘤防治研究, 2014, 41(03): 269-273. DOI: 10.3971/j.issn.1000-8578.2014.03.016
引用本文: 结外鼻型NK/T细胞淋巴瘤组织中MMP-26、MMP-9、TIMP-4 的表达及意义[J]. 肿瘤防治研究, 2014, 41(03): 269-273. DOI: 10.3971/j.issn.1000-8578.2014.03.016
Expression and Significance of MMP-26,TIMP-4 and MMP-9 in Extranodal Natural Killer (NK)/T-cell Lymphoma, Nasal type (ENKTCL) Lymphoma Cells[J]. Cancer Research on Prevention and Treatment, 2014, 41(03): 269-273. DOI: 10.3971/j.issn.1000-8578.2014.03.016
Citation: Expression and Significance of MMP-26,TIMP-4 and MMP-9 in Extranodal Natural Killer (NK)/T-cell Lymphoma, Nasal type (ENKTCL) Lymphoma Cells[J]. Cancer Research on Prevention and Treatment, 2014, 41(03): 269-273. DOI: 10.3971/j.issn.1000-8578.2014.03.016

结外鼻型NK/T细胞淋巴瘤组织中MMP-26、MMP-9、TIMP-4 的表达及意义

Expression and Significance of MMP-26,TIMP-4 and MMP-9 in Extranodal Natural Killer (NK)/T-cell Lymphoma, Nasal type (ENKTCL) Lymphoma Cells

  • 摘要: 目的 通过检测结外鼻型NK/T细胞淋巴瘤(Extranodal natural -type NK/T-cell lymphoma, ENKTCL)组织中的基质金属蛋白酶-26 (MMP-26) 、金属蛋白酶组织抑制剂-4(TIMP-4)、基质金属蛋白酶-9(MMP-9)的表达情况,探讨它们与ENKTCL发病及侵袭性的关系。方法 采用免疫组织化学SABC法检测 30例ENKTCL组织中MMP-26、TIMP-4、MMP-9的表达情况,同时与20例淋巴组织反应性增生进行比较。并分析它们与ENKTCL临床病理指标的关系。结果 ENKTCL组中MMP-26、TIMP-4、MMP-9阳性表达分别为76.67%(23/30)、46.67%(14/ 30)和83.33%(25/ 30);淋巴组织反应性增生组阳性表达率为10% (2/20)、5% (1/20)、15% (3/20)。ENKTCL组MMP-26、TIMP-4、MMP-9 阳性表达率与淋巴组织反应性增生组比较差异有统计学意义(P <0. 05), MMP-26、MMP-9 表达阳性率与临床分期相关,Ⅲ、Ⅳ期患者MMP-26、MMP- 9蛋白的表达阳性率明显高于Ⅰ、Ⅱ期患者 ( P < 0.05),而与年龄、性别无关 (P > 0.05);TIMP-4蛋白的表达与临床分期、年龄、性别均无关( P >0.05)。 ENKTCL病理组织中MMP-26 与TIMP-4表达无相关性,与MMP-9 蛋白的表达呈正相关(rs= 0.636,P <0.05)。结论 MMP-26、MMP-9 在ENKTCL肿瘤组织中存在高表达,可能与ENKTCL的发病及高度侵袭性有关, 并且可能成为鉴别恶性ENKTCL和反应性淋巴结增生的指标,有利于ENKTCL预后的评估。

     

    Abstract: Objective To investigate the correlations between the expressions of matrix metalloprpteinsae 26(MMP-26),tissue inhibitor of metalloproteinase-4 (TIMP-4) and matrix metalloprpteinsae-9 (MMP-9) in patients with Extranodal natural-type NK/T-cell lymphoma (ENKTCL) and invasion of ENKTCL. Methods Expressions of MMP-26, TIMP-4 and MMP-9 were tested by SABC immunohistochemistry in 30 Specimens excised from ENKTCL patients, compairing with 20 cases of reactive lymphoid hyperplasia. The correlation between the expression levels and ENKTCL clinicopathology indexes were analyzed. Results The expression positive rates of MMP-26,TIMP-4 and MMP-9 in ENKTCL were 76.67%(23/30), 46.67%(14/30) and 83.33%(25/30) respectively, and signifi cant higher than those??10%(2/20), 5%(1/20) and 15%(3/20) in patients with reactive lymphoid hyperplasia(P<0.05). The positive expression rates of MMP-26 and MMP-9 were linked to clinical staging but age and gender (P > 0.05). The positive protein expressions in Stage Ⅲ and Ⅳwere higher than those in stageⅠand Ⅱ(P < 0.05), And there was no correlation between the expression of TIMP-4 and clinical staging, age or gender (P > 0.05). MMP-26 expression was related to MMP-9 (rs= 0.636, P <0.05), not to TIMP-4 in patients with ENKTCL (P > 0.05). Conclusion Highexpressions of MMP-26 and MMP-9 in patients with ENKTCL were related to the biological progression and invasiveness of ENKTCL and were malignant indicators to identify ENKTCL from reactive lymph node hyperplasia. MMP-26 and MMP-9 might play roles to assess ENKTCL prognosis.

     

/

返回文章
返回